Figure 2.
Figure 2. Time to progression (TTP) calculated from the start of imatinib treatment for all 27 patients. Estimated median TTP for all patients was 6.6 months (range, 0.9-31 months). The estimated progression-free survival rate for all patients was 48% ±10% at 6.6 months without censoring at the time of imatinib discontinuation.

Time to progression (TTP) calculated from the start of imatinib treatment for all 27 patients. Estimated median TTP for all patients was 6.6 months (range, 0.9-31 months). The estimated progression-free survival rate for all patients was 48% ±10% at 6.6 months without censoring at the time of imatinib discontinuation.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal